{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-23-000084","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.220448+00:00","generated_at":"2026-06-15T23:40:36.062585+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artivion Q1 revenue $83.2M (+8% GAAP, +10% constant currency); raises FY guidance","bullets":["Net loss ($13.5M) or ($0.33)/share; non-GAAP net income $769k ($0.02)/share.","On-X revenue up 24% constant currency; aortic stent grafts up 8% constant currency.","FY 2023 revenue guidance raised to $337-348M (prev. $331-343M); constant currency growth now 9-12%.","Adjusted EBITDA guidance increased to >$52M (prev. >$50M); EBITDA growth >25% YoY expected.","FDA issued Approvable Letter for PerClot PMA; $14.3M milestone payment expected after final approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-23-000084","json":"https://secwatch.observer/filing/0000784199-23-000084.json","markdown":"https://secwatch.observer/filing/0000784199-23-000084.md","text":"https://secwatch.observer/filing/0000784199-23-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419923000084/0000784199-23-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419923000084/aort-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T23:40:36.062585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8953613ef63c4d9247641a842128b71070de08c1","claim":"ARTIVION, INC. updated its full year 2023 guidance (raised).","evidence_excerpt":"Artivion is raising its revenue guidance range and now expects constant currency revenue growth of between 9% and 12%, compared to the previous range of between 8% and 12%, for the full year 2023 compared to 2022. The Company expects revenues to be in a range of between $337.0 million and $348.0 million, compared to the previous range of between $331.0 million and $343.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/784199/000078419923000084/0000784199-23-000084-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"acd0a2768b2ec498a41e30b0a5320b44f492b903","claim":"ARTIVION, INC. reported first quarter ended March 31, 2023 results: revenue $83.2 million, net income ($13.5) million, EPS ($0.33) per fully diluted common share.","evidence_excerpt":"Total revenues for the first quarter of 2023 were $83.2 million, an increase of 8% on a GAAP basis and an increase of 10% on a non-GAAP constant currency basis, both compared to the first quarter of 2022. Net loss for the first quarter of 2023 was ($13.5) million, or ($0.33) per fully diluted common share, compared to net loss of ($3.4) million, or ($0.08) per fully diluted common share for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/784199/000078419923000084/0000784199-23-000084-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$83.2 million"},{"label":"Net income","value":"($13.5) million"},{"label":"EPS","value":"($0.33) per fully diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}